Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer
, et
17 sept. 2016
À propos de cet article
Catégorie d'article: Research Article
Publié en ligne: 17 sept. 2016
Pages: 4 - 16
Reçu: 24 févr. 2016
Accepté: 04 août 2016
DOI: https://doi.org/10.1515/fco-2016-0005
Mots clés
© 2016
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical trials using various therapeutic vaccines_
STUDY NAME | TARGET ANTIGEN | VACCINE NAME/TYPE | CANCER |
---|---|---|---|
IMPACT | PAP | Mo/DCsPAP-GM-CSF | mCRPC |
PROSPECT | PSA | PSA-TRICOM | mCRPC |
Stimuvax | MUC1 | BLPD25 | NSCLC |
PANVAC | MUC1/CEA | DCsPSA-TRICOM | Colorectal |
GVAX | multiple | T47D&SKBR3 lines | Breast |
DERMA | MAGE-A3 | Rec Protein | Melanoma |
MAGRIT | MAGE-A3 | Rec Protein | NSCLC |
IMPRINT | 11 tumour peptides | soluble | Renal |
TG4010 | MUC1 | MVA MUC-1-IL-2 | Prostate NSCLC |
CDX110 | EGFRvIII | Soluble 13-mer | Glioblastoma |